Contact us
Please fill out the details below and we will get back to you shortly.
Thank you!
We will be contacting you soon..
Close
We will be contacting you soon..
Oops! Something went wrong while submitting the form.
October 1, 2023 - In a special feature by Drug Development and Delivery, Dr. Anquetil, PHD, MBA, CEO and Founder of Portal Instruments, explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability.
Portal Instruments: PFS Addresses Variety of Injection Challenges
October 1, 2023 - Portal Instruments, led by Dr. Patrick Anquetil, PHD, MBA, CEO and Founder, is setting a new standard in drug delivery with its groundbreaking PRIME device. In a special feature, Dr. Anquetil explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability. This needle-free injection device offers a revolutionary approach to high viscosity therapies, addressing challenges such as needle fear, injection pain, and the need for real-time tracking and reminders.
Read the full Drug Development and Delivery special feature here.
July 2021 - Many undergraduate students get the opportunity to complete a summer internship. Some participate in a Co-Op; a 6-month long internship where students are able to fully immerse themselves in a full-time employment position to better understand their place in the workspace.
November 21, 2023 - Patrick Anquetil, CEO of Portal Instruments, takes the stage at LSI's 2023 Emerging MedTech Summit in Dana Point, California. Tune in to the recorded session to hear Dr. Anquetil dive into the innovative world of of needle-free and Portal's groundbreaking needle-free technology.
June 30, 2021 - The National Transgender Discrimination Survey Report on Health and Health Care recorded at least 80% of transgender people have either taken gender-affirming hormone therapy (GAHT) or want to take GAHT at some point.¹
Please fill out the details below and we will get back to you shortly.